Tris Pharma Announces Hiring of New Vice President of Quality & Compliance

Monday, August 27, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MONMOUTH JUNCTION, N.J., Aug. 27, 2018 /PRNewswire/ -- Tris Pharma, Inc. (Tris), a  pharmaceutical company focused on developing

innovative technology-based therapeutic products that address unmet patient needs today announced the joining of Jeffery Palmer as its new Vice President and Head of Quality & Compliance.

Jeffrey has worked

for both large and mid-size pharmaceutical companies, and brings more than 20 years of pharmaceutical industry  experience – including his most recent experience as site Head of Quality and his prior experience in Quality Management Systems, Compliance, Process improvement and Scale-up.   A chemical engineer by training, Jeffrey began his pharmaceutical career at Alpharma (Actavis/Teva) as a Validation Engineer in Maryland, and then worked ten plus years in global quality systems at Schering-Plough/Merck, rising to Associate Director. For almost the past 4 years he has been at Lupin Pharmaceuticals, and most recently served as Quality head for its Somerset, NJ site where he managed all aspects of quality and compliance. Jeffrey holds a Chemical Engineering degree from Clarkson University and has an MBA from the University of Maryland.

"Jeffrey's background, especially his experience in Quality Systems with his early focus on validation/process improvement makes him an ideal candidate as the Head of Quality & Compliance for Tris" said Ketan Mehta, President and Chief Executive Officer of Tris.  "His successful track record in developing sustainable quality management systems, creating a company-wide quality culture and developing right-first-time teams that bring high-quality products to market is what Tris needs today."

"I am honored to have the opportunity to lead the Tris Quality organization, and will do my part to ensure the highest standards of quality and continuous improvement at Tris. I am excited to work with my colleagues at Tris to serve the patients who depend on our products." said Jeffrey Palmer.

Jack Goodson, FDA's former National expert of Generic Drugs and Biologics, who has been Tris' interim Head of Quality & Compliance for the past five months will continue to assist the Tris team as a consultant working with Jeffrey through the transition and focus on other compliance priorities.

About Tris Pharma

Tris Pharma is a fully integrated pharmaceutical company focused on the development of innovative medicines that address unmet patient needs. Using its proprietary technology platform, LiquiXR®, Tris has pioneered the delivery of sustained release in the liquid, chewable, orally disintegrating tablet, and other dosage forms that benefits a wide variety of patients and their unique needs. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' research, manufacturing and commercial facilities are located in Central New Jersey. For more information, please visit


Cision View original content:

SOURCE Tris Pharma, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store